DLL4 expression is a prognostic marker and may predict gemcitabine benefit in resected pancreatic cancer

por Drouillard, A, Puleo, F, Bachet, J B, Ouazzani, S, Calomme, A, Demetter, P, Verset, G, Van Laethem, J L, Maréchal, R
Publicado 2016

Relevance of biopsy-derived pancreatic organoids in the development of efficient transcriptomic signatures to predict adjuvant chemosensitivity in pancreatic cancer

por Nicolle, R., Gayet, O., Bigonnet, M., Roques, J., Chanez, B., Puleo, F., Augustin, J., Emile, J.F., Svrcek, M., Arsenijevic, T., Hammel, P., Rebours, V., Giovannini, M., Grandval, P., Dahan, L., Moutardier, V., Mitry, E., Van Laethem, J.L., Bachet, J.B., Cros, J., Iovanna, J., Dusetti, N.J.
Publicado 2021